Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07012486

Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia

The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is:

• Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA.

Participants will:

* Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months. * Visit the clinic once every month for checkups and tests.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Androgenetic Alopecia (AGA) Alopecia Hair Diseases Hypotrichosis Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Early Phase 1

Primary location

Zhongshan Hospital Fudan University

Shanghai, Shanghai Municipality, 200032, China

Location status: Recruiting

Location contact

Lujuan, MD, PhD

CONTACT

[email protected]

86-021-64041990

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinically diagnosed with androgenetic alopecia (AGA)
  • No pregnancy plans within the next 6 months

Exclusion criteria

  • Patients who received systemic medications for hair loss within the past 2 months
  • Use of topical medication for hair loss within the past 2 weeks
  • Pregnancy or lactation
  • Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.

Treatment and study plan

Oral DHA + Topical minoxidil 5%

Drug

DHA 20mg tid po plus daily topical minoxidil 5% for 180 days

Topical minoxidil 5%

Drug

Topical minoxidil 5% daily for 180 days

Primary outcomes

  1. Improvement in terminal hair follicles in the vertex area

    Time frame: Baseline and 180-day of treatment

    Terminal hair follicles in the vertex area will be quantified before and at the end of treatment

Secondary outcomes

  1. Change of terminal hair follicle density in the vertex area from baseline to the end of treatment

    Time frame: Baseline and 180-day of treatment

  2. Change of hair density in the vertex area from baseline to the end of treatment

    Time frame: Baseline and 180-day of treatment

  3. Change of terminal hair follicle density in the frontal area from baseline to the end of treatment

    Time frame: Baseline and 180-day of treatment

    Terminal hair follicle density in the frontal area

  4. Change of hair density in the frontal area from baseline to the end of treatment

    Time frame: Baseline and 180-day of treatment

  5. Change of serum total testosterone from baseline to the end of treatment

    Time frame: Baseline and 180-day of treatment

Study contacts

Contact information is provided by the study sponsor or research team.

Lujuan GAO, MD, PhD

CONTACT

[email protected]

86-021-64041990

Sponsors and collaborators

Lead sponsor

Shanghai Zhongshan Hospital

Other

Registry information

Official study title

A Pilot Study to Evaluate the Therapeutic Effect of Dihydroartemisinin on Female Androgenetic Alopecia

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jun 10, 2025
Registry last updated
Jun 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.